Occlutech's Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation
SCHAFFHAUSEN, Switzerland, Dec. 18, 2020 -- (Healthcare Sales & Marketing Network) -- Occlutech, a privately-held company, announced today that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its fir... Devices, Interventional, Cardiology, FDA Occlutech, Atrial Flow Regulator, Pulmonary Arterial Hypertension
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Food and Drug Administration (FDA) | Heart | Hypertension | Marketing | Pharmaceuticals | Switzerland Health